- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Medirom Healthcare Technologies Inc. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 21.03. | Medirom Healthcare Technologies Inc. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 17.03. | MEDIROM Healthcare Technologies Inc. Announces New JPY350 Million (Approximately $2.4 Million) Unsecured Loan Financing | 167 | GlobeNewswire (Europe) | TOKYO, March 17, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Nasdaq CM: MRM), a holistic healthcare company based in Japan (the "Company" or "MEDIROM"), today announced that it... ► Artikel lesen | |
| 13.03. | MEDIROM Healthcare Technologies Inc.: MEDIROM Mother Labs Executive Makes Additional Investment in Mother Labs' Series A Financing at a Pre-Money Valuation of JPY9 Billion (as of March 13, 2025, Approximately US$60 Million) | 2 | GlobeNewswire (USA) | ||
| MEDIROM HEALTHCARE TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 13.03. | Medirom Healthcare Technologies Inc. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 04.03. | Medirom Healthcare Technologies Inc. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 18.02. | MEDIROM Healthcare sees FY24 revenue to be about JPY8.2B | 1 | Seeking Alpha | ||
| 18.02. | MEDIROM Healthcare Technologies Inc. Announces Preliminary, Unaudited Financial Results for Full Year 2024 Under Japanese GAAP | 188 | GlobeNewswire (Europe) | NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Nasdaq CM: MRM), a holistic healthcare company based in Japan (the "Company"), today announced its preliminary, unaudited... ► Artikel lesen | |
| 18.02. | Medirom Healthcare Technologies Inc. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 29.01. | MEDIROM Healthcare Technologies Inc. Announces December 2024 Key Performance Indicators (KPIs) | 1 | GlobeNewswire (USA) | ||
| 29.01. | Medirom Healthcare Technologies Inc. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 21.01. | MEDIROM Healthcare Technologies Inc.: Completion of Offering and Increase in Registered Capital | 11 | GlobeNewswire (USA) | ||
| 21.01. | MEDIROM Healthcare Technologies Inc.: MEDIROM MOTHER Labs Provides MOTHER Bracelet? Device and Remote Health Monitoring System, REMONY, to TOPPAN Inc. | 6 | GlobeNewswire (USA) | ||
| 21.01. | Medirom Healthcare Technologies Inc. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 23.12.24 | MEDIROM verzeichnet moderates Wachstum bei November-KPIs | 1 | Investing.com Deutsch | ||
| 23.12.24 | MEDIROM reports modest growth in November KPIs | 1 | Investing.com | ||
| 23.12.24 | MEDIROM Healthcare Technologies Inc. Announces November 2024 Key Performance Indicators (KPIs) | 2 | GlobeNewswire (USA) | ||
| 23.12.24 | Medirom Healthcare Technologies Inc. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 13.12.24 | MEDIROM Healthcare Technologies Inc.: MEDIROM Healthcare Technology's Subsidiary, MEDIROM MOTHER Labs, Raises an Aggregate Total of JPY260.3 Million in its Series A Financing Round | 4 | GlobeNewswire (USA) | ||
| 13.12.24 | Medirom Healthcare Technologies Inc. - 6-K, Report of foreign issuer | - | SEC Filings |
Seite:
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,139 | +5,30 % | Sernova Aktie: Positives Umsatzwachstum gemeldet! | Das Biotechnologieunternehmen erweitert sein Führungsteam, sichert Finanzierungen und erhält FDA-Freigabe für klinische Studien zur Behandlung von Hypothyreose. Sernova Biotherapeutics, ehemals Sernova... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,639 | -0,93 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio | SEATTLE, April 22, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast... ► Artikel lesen | |
| PING AN HEALTHCARE | 0,804 | 0,00 % | Ping An Healthcare and Technology Company Limited: Ping An Health Reports 25.8% Year-on-Year Revenue Growth in Q1 2025, with Profitability Accelerating | Revenue and Profit Surge, Driven by "AI + Health Care" Value Empowerment
SHANGHAI and HONG KONG, April 24, 2025 /PRNewswire/ -- Ping An Healthcare and Technology... ► Artikel lesen | |
| MOUNTAIN VALLEY MD | 0,013 | 0,00 % | Mountain Valley MD Holdings Inc: Mountain Valley hopes for continued growth in 2025 | ||
| CO-DIAGNOSTICS | 0,312 | -0,64 % | Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results | SALT LAKE CITY, March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the... ► Artikel lesen | |
| CYTOSORBENTS | 1,060 | +4,54 % | CytoSorbents Gains $1.7M Via NJEDA Tax Credit Sale To Fund Strategic Growth | ||
| VERU | 0,468 | -3,70 % | Veru Aktie: Bedeutet das eine Neuausrichtung? | Die Veru-Aktie verliert weiter an Wert, doch Analysten bleiben optimistisch aufgrund vielversprechender Medikamentenentwicklungen. Wird der Tiefpunkt bald erreicht? Die Veru-Aktie setzt ihre Abwärtsspirale... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 7,050 | -100,00 % | Tempest Therapeutics: Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP | BRISBANE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics... ► Artikel lesen | |
| VOLITIONRX | 0,482 | 0,00 % | VOLITIONRX LTD - 8-K, Current Report | ||
| EKSO BIONICS | 0,360 | -4,76 % | Ekso Bionics Holdings, Inc.: Bionic P&O Chosen as First Distributor of Ekso Indego Personal Within the Orthotics & Prosthetics Industry | ||
| IMUNON | 0,770 | -1,91 % | Imunon, Inc.: IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting | ||
| BEYOND AIR | 0,193 | +4,89 % | Beyond Air: NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism | The FDA designation marks a significant milestone in the development of a novel treatment for a rare neurodevelopmental disorder Plan to initiate first-in-human U.S. clinical trials of lead drug candidate... ► Artikel lesen | |
| AVINGER | 0,340 | -6,08 % | Avinger, Inc.: Avinger Reports Third Quarter 2024 Results | Lower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin REDWOOD CITY, CA / ACCESSWIRE / November 7, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company... ► Artikel lesen | |
| NOVACYT | 0,473 | +4,53 % | Novacyt legt Termin für Finanzergebnisse 2024 fest | ||
| AROVELLA THERAPEUTICS | 0,049 | +2,08 % | AROVELLA THERAPEUTICS LIMITED: Notification regarding unquoted securities - ALA |
MEDIROM HEALTHCARE TECHNOLOGIES INC ADR gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 0,780 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDIROM HEALTHCARE TECHNOLOGIES INC ADR finden Sie auf Wallstreet Online.
